Locoregional recurrence in triple negative breast cancer: past, present, and future

References

• Wu X, Baig A, Kasymjanova G, et al. Pattern of local recurrence and distant metastasis in breast cancer by molecular subtype. Cureus. 2016. Epub ahead of print. doi: 10.7759/cureus.924
   Google Scholar
• Morrow M. Personalizing extent of breast cancer surgery according to molecular subtypes. The Breast. 2013;22:S106–S109. Epub ahead of print. doi: 10.1016/j.breast.2013.07.020
   PubMedGoogle Scholar
• Buchholz TA, Ali S, Hunt KK. Multidisciplinary management of locoregional recurrent breast cancer. JCO. 2020;38(20):2321–2328. Epub ahead of print. doi: 10.1200/JCO.19.02806
   PubMed Web of Science ®Google Scholar
• Smith TE, Lee D, Turner BC, et al. True recurrence vs. new primary ipsilateral breast tumor relapse: an analysis of clinical and pathologic differences and their implications in natural history, prognoses, and therapeutic management. Int J Radiat Oncol Biol Phys. 2000;48(5):1281–1289. Epub ahead of print. doi: 10.1016/S0360-3016(00)01378-X
   PubMed Web of Science ®Google Scholar
• Buchanan CL, Dorn PL, Fey J, et al. Locoregional recurrence after Mastectomy: incidence and outcomes. J Of The Am Coll Of Surgeons. 2006;203(4):469–474. Epub ahead of print. doi: 10.1016/j.jamcollsurg.2006.06.015
   PubMed Web of Science ®Google Scholar
• Witteveen A, Kwast ABG, Sonke GS, et al. Survival after locoregional recurrence or second primary breast cancer: impact of the disease-free interval. PLoS One. 2015;10(4):e0120832. Epub ahead of print. doi: 10.1371/journal.pone.0120832
   PubMed Web of Science ®Google Scholar
• Shikama N, Sekiguchi K, Nakamura N. Management of locoregional recurrence of breast cancer. Breast Cancer. 2011;18(4):252–258. doi: 10.1007/s12282-010-0206-9
   PubMed Web of Science ®Google Scholar
• Zhang C, Wang S, Israel HP, et al. Higher locoregional recurrence rate for triple-negative breast cancer following neoadjuvant chemotherapy, surgery and radiotherapy. Springerplus. 2015;4(1): Epub ahead of print. doi: 10.1186/s40064-015-1116-2
   Google Scholar
• Merino T, Ip T, Domínguez F, et al. Risk factors for loco-regional recurrence in breast cancer patients: a retrospective study. Oncotarget. 2018;9(54):30355–30362. Epub ahead of print. doi: 10.18632/oncotarget.25735
   PubMedGoogle Scholar
• Wapnir IL, Anderson SJ, Mamounas EP, et al. Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five national surgical adjuvant breast and bowel project node-positive adjuvant breast cancer trials. JCO. 2006;24(13):2028–2037. Epub ahead of print. doi: 10.1200/JCO.2005.04.3273
   PubMed Web of Science ®Google Scholar
• Anderson SJ, Wapnir I, Dignam JJ, et al. Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five national surgical adjuvant breast and bowel project protocols of node-negative breast cancer. JCO. 2009;27(15):2466–2473. Epub ahead of print. doi: 10.1200/JCO.2008.19.8424
   PubMed Web of Science ®Google Scholar
• Halverson KJ, Perez CA, Kuske RR, et al. Isolated local-regional recurrence of breast cancer following mastectomy: radiotherapeutic management. Int J Radiat Oncol Biol Phys. 1990;19(4):851–858. Epub ahead of print. doi: 10.1016/0360-3016(90)90004-4
   PubMed Web of Science ®Google Scholar
• Nielsen HM, Overgaard M, Grau C, et al. Loco-regional recurrence after mastectomy in high-risk breast cancer—risk and prognosis. An analysis of patients from the DBCG 82 b&c randomization trials. Radiother And Oncol. 2006;79(2):147–155. Epub ahead of print. doi: 10.1016/j.radonc.2006.04.006
   PubMed Web of Science ®Google Scholar
• Baranova A, Krasnoselskyi M, Starikov V, et al. Triple-negative breast cancer: current treatment strategies and factors of negative prognosis. JMedLife. 2022;15(2):153–161. Epub ahead of print. doi: 10.25122/jml-2021-0108
   Google Scholar
• Wapnir IL, Price KN, Anderson SJ, et al. Efficacy of chemotherapy for ER-negative and ER-positive isolated locoregional recurrence of breast cancer: final analysis of the CALOR trial. J Clin Oncol. 2018;36(11):1073–1079. Epub ahead of print. doi: 10.1200/JCO.2017.76.5719
   PubMed Web of Science ®Google Scholar
• Kumar P, Aggarwal R. An overview of triple-negative breast cancer. Arch Gynecol Obstetrics. 2016;293(2):247–269. Epub ahead of print. doi: 10.1007/s00404-015-3859-y
   PubMed Web of Science ®Google Scholar
• Goel A, Agarwal VK, Nayak V, et al. Surgical management of locoregional recurrence in breast cancer. Indian J Surg Oncol. 2021;12(3):616–623. Epub ahead of print. doi: 10.1007/s13193-021-01342-4
   PubMed Web of Science ®Google Scholar
• Alpert TE, Kuerer HM, Arthur DW, et al. Ipsilateral breast tumor recurrence after breast conservation therapy: outcomes of salvage mastectomy vs. salvage breast-conserving surgery and prognostic factors for salvage breast preservation. Int J Radiat Oncol Biol Phys. 2005;63(3):845–851. Epub ahead of print. doi: 10.1016/j.ijrobp.2005.02.035
   PubMed Web of Science ®Google Scholar
• Gentilini O, Botteri E, Veronesi P, et al. Repeating conservative surgery after ipsilateral breast tumor reappearance: criteria for selecting the best candidates. Ann Surg Oncol. 2012;19(12):3771–3776. Epub ahead of print. doi: 10.1245/s10434-012-2404-5
   PubMed Web of Science ®Google Scholar
• Lee CH, Cheng MH, Wu CW, et al. Nipple-sparing mastectomy and immediate breast reconstruction after recurrence from previous breast conservation therapy. Ann Plast Surg. 2019;82(1S):S95–S102. Epub ahead of print. doi: 10.1097/SAP.0000000000001696
   PubMedGoogle Scholar
• H W, G A, C C, et al. Current treatment of isolated locoregional breast cancer recurrences. Breast Care 2015;10:265–271.
   PubMed Web of Science ®Google Scholar
• Faneyte IF, Rutgers EJT, Zoetmulder FAN. Chest wall resection in the treatment of locally recurrent breast carcinoma: indications and outcome for 44 patients. Cancer 1997;80. Epub ahead of print. doi: 10.1002/(SICI)1097-0142(19970901)80:5<886:AID-CNCR9>3.0.CO;2-J
   PubMed Web of Science ®Google Scholar
• Lu X, He M, Yu L, et al. Is repeat sentinel lymph node biopsy possible for surgical axillary staging among patients with ipsilateral breast tumor recurrence? Cancer. 2023;129(10):1492–1501. Epub ahead of print. doi: 10.1002/cncr.34708
   PubMed Web of Science ®Google Scholar
• Poodt IGM, Walstra CJEF, Vugts G, et al. Low risk of development of a regional recurrence after an unsuccessful repeat sentinel lymph node biopsy in patients with ipsilateral breast tumor recurrence. Ann Surg Oncol. 2019;26(8):2417–2427. Epub ahead of print. doi: 10.1245/s10434-019-07272-4
   PubMed Web of Science ®Google Scholar
• Kelley BP, Ahmed R, Kidwell KM, et al. A systematic review of morbidity associated with autologous breast reconstruction before and after exposure to radiotherapy: are current practices ideal? Ann Surg Oncol. 2014;21(5):1732–1738. Epub ahead of print. doi: 10.1245/s10434-014-3494-z
   PubMed Web of Science ®Google Scholar
• Momoh AO, Ahmed R, Kelley BP, et al. A systematic review of complications of implant-based breast reconstruction with prereconstruction and postreconstruction radiotherapy. Ann Surg Oncol. 2014;21(1):118–124. Epub ahead of print. doi: 10.1245/s10434-013-3284-z
   PubMed Web of Science ®Google Scholar
• Chetta MD, Aliu O, Zhong L, et al. Reconstruction of the irradiated breast: a national claims-based assessment of postoperative morbidity. Plast Reconstr Surg. 2017;139(4):783–792. Epub ahead of print. doi: 10.1097/PRS.0000000000003168
   PubMed Web of Science ®Google Scholar
• Xavier Harmeling J, Kouwenberg CAE, Bijlard E, et al. The effect of immediate breast reconstruction on the timing of adjuvant chemotherapy: a systematic review. Breast Cancer Res Treat. 2015;153(2):241–251. Epub ahead of print. doi: 10.1007/s10549-015-3539-4
   PubMed Web of Science ®Google Scholar
• Varghese J, Gohari SS, Rizki H, et al. A systematic review and meta-analysis on the effect of neoadjuvant chemotherapy on complications following immediate breast reconstruction. Breast. 2021;55. doi: 10.1016/j.breast.2020.11.023. Epub ahead of print.
   PubMed Web of Science ®Google Scholar
• Eiermann W, Vallis KA. Locoregional treatments for triple-negative breast cancer. Ann Oncol 2012;23. Epub ahead of print. doi: 10.1093/annonc/mds192
   Google Scholar
• Yang PS, Chen CM, Liu MC, et al. Radiotherapy can decrease locoregional recurrence and increase survival in mastectomy patients with T1 to T2 breast cancer and One to three positive nodes with negative estrogen receptor and positive lymphovascular invasion status. Int J Radiat Oncol Biol Phys. 2010;77(2):516–522. Epub ahead of print. doi: 10.1016/j.ijrobp.2009.05.016
   PubMed Web of Science ®Google Scholar
• Siglin J, Champ CE, Vakhnenko Y, et al. Radiation therapy for locally recurrent breast cancer. Int J Breast Cancer. 2012;2012:1–7. doi: 10.1155/2012/571946
   Google Scholar
• Fattahi S, Ahmed SK, Park SS, et al. Reirradiation for locoregional recurrent breast cancer. Adv Radiat Oncol. 2021;6(1):100640. Epub ahead of print. doi: 10.1016/j.adro.2020.100640
   PubMedGoogle Scholar
• Wapnir IL, Khan A. Current strategies for the management of locoregional breast cancer recurrence. Oncol. 2019;33:19–25.
   Google Scholar
• Arthur DW, Winter KA, Kuerer HM, et al. Effectiveness of breast-conserving surgery and 3-dimensional conformal partial breast reirradiation for recurrence of breast cancer in the ipsilateral breast: the NRG Oncology/RTOG 1014 phase 2 clinical trial. JAMA Oncol. 2020;6(1):75. Epub ahead of print. doi: 10.1001/jamaoncol.2019.4320
   PubMed Web of Science ®Google Scholar
• Walstra CJEF, Schipper RJ, Poodt IGM, et al. Repeat breast-conserving therapy for ipsilateral breast cancer recurrence: a systematic review. Eur J Of Surg Oncol. 2019;45(8):1317–1327. Epub ahead of print. doi: 10.1016/j.ejso.2019.02.008
   PubMed Web of Science ®Google Scholar
• Würschmidt F, Dahle J, Petersen C, et al. Reirradiation of recurrent breast cancer with and without concurrent chemotherapy. Radiat Oncol. 2008;3. Epub ahead of print. doi: 10.1186/1748-717X-3-28
   PubMed Web of Science ®Google Scholar
• Montagne L, Hannoun A, Hannoun-Levi JM. Second conservative treatment for second ipsilateral breast tumor event: a systematic review of the different re-irradiation techniques. Breast 2020;49. Epub ahead of print. doi: 10.1016/j.breast.2020.01.003
   PubMed Web of Science ®Google Scholar
• Gabani P, Patel H, Thomas MA, et al. Clinical outcomes and toxicity of proton beam radiation therapy for re-irradiation of locally recurrent breast cancer. Clin Transl Radiat Oncol Epub ahead of print. 2019;19:116–122. doi: 10.1016/j.ctro.2019.09.005
   PubMed Web of Science ®Google Scholar
• Notter M, Thomsen AR, Nitsche M, et al. Combined wIRA-hyperthermia and hypofractionated re-irradiation in the treatment of locally recurrent breast cancer: evaluation of therapeutic outcome based on a novel size classification. Cancers (Basel). 2020;12(3):606. Epub ahead of print. doi: 10.3390/cancers12030606
   PubMed Web of Science ®Google Scholar
• Linthorst M, Van Geel AN, Baaijens M, et al. Re-irradiation and hyperthermia after surgery for recurrent breast cancer. Radiother and Oncol. 2013;109(2):188–193. Epub ahead of print. doi: 10.1016/j.radonc.2013.05.010
   PubMed Web of Science ®Google Scholar
• Harms W, Krempien R, Hensley FW, et al. Results of chest wall reirradiation using pulsed-dose-rate (PDR) brachytherapy molds for breast cancer local recurrences. Int J Radiat Oncol Biol Phys. 2001;49(1):205–210. Epub ahead of print. doi: 10.1016/S0360-3016(00)01360-2
   PubMed Web of Science ®Google Scholar
• Harkenrider MM, Wilson MR, Dragun AE. Reirradiation as a component of the multidisciplinary management of locally recurrent breast cancer. Clin Breast Cancer. 2011;11(3):171–176. Epub ahead of print. doi: 10.1016/j.clbc.2011.03.014
   PubMed Web of Science ®Google Scholar
• Hurwitz M, Stauffer P. Hyperthermia, radiation and chemotherapy: the role of heat in multidisciplinary cancer care. Semin In Oncol. 2014;41(6):714–729. Epub ahead of print. doi: 10.1053/j.seminoncol.2014.09.014
   PubMed Web of Science ®Google Scholar
• Resch A, Fellner C, Mock U, et al. Locally recurrent breast cancer: pulse dose rate brachytherapy for repeat irradiation following lumpectomy—A second chance to preserve the breast. Radiol. 2002;225(3):713–718. Epub ahead of print. doi: 10.1148/radiol.2253011913
   PubMed Web of Science ®Google Scholar
• Trombetta M, Julian T, Miften M, et al. The use of the MammoSite balloon applicator in re-irradiation of the breast. Brachytherapy. 2008;7(4):316–319. Epub ahead of print. doi: 10.1016/j.brachy.2008.06.001
   PubMed Web of Science ®Google Scholar
• Deutsch M. Repeat high-dose external beam irradiation for in-breast tumor recurrence after previous lumpectomy and whole breast irradiation. Int J Radiat Oncol Biol Phys. 2002;53(3):687–691. Epub ahead of print. doi: 10.1016/S0360-3016(02)02785-2
   PubMed Web of Science ®Google Scholar
• Oldenborg S, Griesdoorn V, Van Os R, et al. Reirradiation and hyperthermia for irresectable locoregional recurrent breast cancer in previously irradiated area: size matters. Radiother And Oncol. 2015;117(2):223–228. Epub ahead of print. doi: 10.1016/j.radonc.2015.10.017
   PubMed Web of Science ®Google Scholar
• Datta NR, Puric E, Klingbiel D, et al. Hyperthermia and radiation therapy in locoregional recurrent breast cancers: a systematic review and meta-analysis. Int J Radiat Oncol Biol Phys. 2016;94(5):1073–1087. Epub ahead of print. doi: 10.1016/j.ijrobp.2015.12.361
   PubMed Web of Science ®Google Scholar
• Chagpar A, Meric-Bernstam F, Hunt KK, et al. Chest wall recurrence after mastectomy does not always portend a dismal outcome. Ann Surg Oncol. 2003;10(6):628–634. Epub ahead of print. doi: 10.1245/ASO.2003.01.004
   PubMed Web of Science ®Google Scholar
• Kuo SH, Huang CS, Kuo WH, et al. Comprehensive locoregional treatment and systemic therapy for postmastectomy isolated locoregional recurrence. Int J Radiat Oncol Biol Phys. 2008;72(5):1456–1464. Epub ahead of print. doi: 10.1016/j.ijrobp.2008.03.042
   PubMed Web of Science ®Google Scholar
• Skinner HD, Strom EA, Motwani SB, et al. Radiation dose escalation for loco-regional recurrence of breast cancer after mastectomy. Radiat Oncol. 2013;8. Epub ahead of print. doi: 10.1186/1748-717X-8-13
   PubMed Web of Science ®Google Scholar
• Brown LC, Mutter RW, Halyard MY. Benefits, risks, and safety of external beam radiation therapy for breast cancer. Int J Womens Health 2015;7. Epub ahead of print 10.2147/IJWH.S55552
   PubMedGoogle Scholar
• Ramseier JY, Ferreira MN, Leventhal JS. Dermatologic toxicities associated with radiation therapy in women with breast cancer[Formula presented]. Int J of Women’s Dermatol. 2020;6(5):349–356. Epub ahead of print. doi: 10.1016/j.ijwd.2020.07.015
   PubMedGoogle Scholar
• Belkacemi Y, Hanna NE, Besnard C, et al. Local and regional breast cancer recurrences: salvage therapy options in the new Era of molecular subtypes. Front Oncol . 2018;8. Epub ahead of print. doi: 10.3389/fonc.2018.00112
   PubMed Web of Science ®Google Scholar
• Lee K, Sim SH, Kang EJ, et al. The role of chemotherapy in patients with HER2-negative isolated locoregional recurrence of breast cancer: a multicenter retrospective cohort study. Front Oncol. 2021;11. Epub ahead of print.
   Web of Science ®Google Scholar
• Morgan JL, Cheng V, Barry PA, et al. The MARECA (national study of management of breast cancer locoregional recurrence and oncological outcomes) study: national practice questionnaire of United Kingdom multi-disciplinary decision making. Eur J Of Surg Oncol. 2022;48(7):1510–1519. Epub ahead of print. doi: 10.1016/j.ejso.2022.03.017
   PubMed Web of Science ®Google Scholar
• Aebi S, Gelber S, Anderson SJ, et al. Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial. The Lancet Oncology. 2014;15(2):156–163. Epub ahead of print. doi: 10.1016/S1470-2045(13)70589-8
   PubMed Web of Science ®Google Scholar
• Robson M, Im S-A, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377(6):523–533. Epub ahead of print. doi: 10.1056/nejmoa1706450
   PubMed Web of Science ®Google Scholar
• Bardia A, Hurvitz SA, Tolaney SM, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med. 2021;384(16):1529–1541. Epub ahead of print. doi: 10.1056/nejmoa2028485
   PubMed Web of Science ®Google Scholar
• Carey LA, Loirat D, Punie K, et al. Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis. NPJ Breast Cancer. 2022;8. Epub ahead of print. doi: 10.1038/s41523-022-00439-5
   Web of Science ®Google Scholar
• Modi S, Saura C, Yamashita T, et al. Trastuzumab deruxtecan in Previously treated HER2-positive breast cancer. N Engl J Med. 2020;382(7):610–621. Epub ahead of print. doi: 10.1056/nejmoa1914510
   PubMed Web of Science ®Google Scholar
• Keene KS, King T, Hwang ES, et al. Molecular determinants of post-mastectomy breast cancer recurrence. NPJ Breast Cancer. 2018;4. Epub ahead of print. doi: 10.1038/s41523-018-0089-z
   PubMed Web of Science ®Google Scholar
• Hancock BA, Chen YH, Solzak JP, et al. Profiling molecular regulators of recurrence in chemorefractory triple-negative breast cancers. Breast Cancer Res. 2019;21. Epub ahead of print. doi: 10.1186/s13058-019-1171-7
   PubMed Web of Science ®Google Scholar
• Chen X, Li J, Gray WH, et al. Tnbctype: a subtyping tool for triple-negative breast cancer. Cancer Inform. 2012;11. Epub ahead of print. doi: 10.4137/CIN.S9983
   Google Scholar
• Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121(7):2750–2767. Epub ahead of print. doi: 10.1172/JCI45014
   PubMed Web of Science ®Google Scholar
• Lehmann BD, Jovanović B, Chen X, et al. Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection. PLoS One. 2016;11(6):e0157368. Epub ahead of print. doi: 10.1371/journal.pone.0157368
   PubMed Web of Science ®Google Scholar
• Nuyten DSA, Kreike B, Hart AAM, et al. Predicting a local recurrence after breast-conserving therapy by gene expression profiling. Breast Cancer Res. 2006;8. Epub ahead of print. doi: 10.1186/bcr1614
   PubMed Web of Science ®Google Scholar
• Cheng SH, Horng CF, West M, et al. Genomic prediction of locoregional recurrence after mastectomy in breast cancer. JCO. 2006;24(28):4594–4602. Epub ahead of print. doi: 10.1200/JCO.2005.02.5676
   PubMed Web of Science ®Google Scholar
• West NR, Milne K, Truong PT, et al. Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer. Breast Cancer Res. 2011;13. Epub ahead of print. doi: 10.1186/bcr3072
   PubMed Web of Science ®Google Scholar
• Denkert C, Loibl S, Noske A, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. JCO. 2010;28(1):105–113. Epub ahead of print. doi: 10.1200/JCO.2009.23.7370
   PubMed Web of Science ®Google Scholar
• Loi S, Sirtaine N, Piette F, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. JCO. 2013;31(7):860–867. Epub ahead of print. doi: 10.1200/JCO.2011.41.0902
   PubMed Web of Science ®Google Scholar
• Loi S, Michiels S, Salgado R, et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol. 2014;25(8):1544–1550. doi: 10.1093/annonc/mdu112
   PubMed Web of Science ®Google Scholar
• Dieci MV, Mathieu MC, Guarneri V, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials. Ann Oncol. 2015;26(8):1698–1704. Epub ahead of print. doi: 10.1093/annonc/mdv239
   PubMed Web of Science ®Google Scholar
• Adams S, Gray RJ, Demaria S, et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. JCO. 2014;32(27):2959–2966. Epub ahead of print. doi: 10.1200/JCO.2013.55.0491
   PubMed Web of Science ®Google Scholar
• Jiang YZ, Liu YR, Xu XE, et al. Transcriptome analysis of triple-negative breast cancer reveals an integrated mRNA-lncRNA signature with predictive and prognostic value. Cancer Res. 2016;76(8):2105–2114. Epub ahead of print. doi: 10.1158/0008-5472.CAN-15-3284
   PubMed Web of Science ®Google Scholar
• van Roozendaal LM, Smit LHM, Duijsens GHNM, et al. Risk of regional recurrence in triple-negative breast cancer patients: a Dutch cohort study. Breast Cancer Res Treat. 2016;156(3):465–472. Epub ahead of print. doi: 10.1007/s10549-016-3757-4
   PubMed Web of Science ®Google Scholar
• Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382(9):810–821. Epub ahead of print. doi: 10.1056/nejmoa1910549
   PubMed Web of Science ®Google Scholar
• Stecklein SR, Kimler BF, Yoder R, et al. ctDNA and residual cancer burden are prognostic in triple-negative breast cancer patients with residual disease. NPJ Breast Cancer. 2023;9. Epub ahead of print. doi: 10.1038/s41523-023-00512-7
   PubMed Web of Science ®Google Scholar